PROTAGENIC THERAPEUTICS INC (PTIX)
US74365N2027 - Common Stock
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
Protagenic Therapeutics just reported results for the fourth quarter of 2023.
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagenic Therapeutics (NASDAQ:PTIX) just reported results for the fourth quar...
Protagenic Therapeutics says board approved 1-for-4 reverse stock split (NASDAQ:PTIX)
Protagenic Therapeutics (PTIX) on Wednesday announced it has approved a 1-for-4 reverse stock split of the company's issued and outstanding common stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022. The presentation details are as follows: Date: Wednesday, April 27, 2022 Time: 10:30 AM ET Link:
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to...
Maxim Group Thinks Protagenic Therapeutics’ Stock is Going to Recover
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update